Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation (NCT01707368), a registered phase not stated study. The primary outcome is The Course of Disease and Relapse Management During Treatment With Daivobet® Gel Under Consideration of Patient's Individual Application Habits Under Daily Use Conditions..

2. Clinical Question

This is a question about outcomes observed during treatment in daily practice, rather than a question framed around a controlled comparison. Individual application habits are explicitly part of the study’s purpose, making the observed course relevant to the circumstances in which care was delivered. At the same time, treatment use, follow-up, and disease course may vary between participants, and the record does not describe a comparator that could separate treatment effects from those other influences.

The registry also lists physician assessments of psoriasis severity and side effects among secondary outcomes. Those entries indicate additional areas of interest, but the available record does not give their results. It likewise does not describe how the severity assessments were categorized, how relapse was defined, or how repeated treatment was recorded. Accordingly, the clinical question can be described from the study aims, but its answer cannot be reconstructed from the registry record.

3. Trial Design

This was a completed, non-interventional study sponsored by LEO Pharma. Its stated purpose was to document the course of psoriasis and relapse management during treatment with Daivobet® Gel, taking account of participants’ individual application habits under daily-use conditions. Enrollment was 561. The registry record identifies psoriasis vulgaris and plaque psoriasis as the conditions of interest.

The recorded treatment regimen was Daivobet® Gel once daily on areas with plaque psoriasis. Treatment duration was up to 8 weeks for body skin areas other than the scalp and up to 4 weeks for the scalp; treatment could be repeated under medical surveillance. These details describe the regimen recorded for eligible patients. They do not establish how consistently participants followed it, how often treatment was repeated, or whether every enrolled participant received treatment as described. Those details are not reported in the registry record.

The study was not a randomized comparison. The allocation method is not stated, and no like-for-like control arm is described. The record therefore supports a description of outcomes observed in the study population, not a comparison of outcomes under alternative assigned treatments. The number of participants who contributed to the primary outcome is not reported; the outcome population is defined as participants with at least one observation after baseline.

The study is listed as completed. Its recorded start was 2012-10 and its primary completion was 2014-05. The primary outcome timeframe was one year. The registry lists secondary outcomes concerning physician assessment of psoriasis vulgaris severity and side effects. It reports four outcome measures and zero analyses. The record does not provide a statistical analysis plan, details of follow-up schedules, eligibility criteria, or a participant flow account. As a result, the broad design and intended observations are identifiable, while important operational details needed to assess implementation are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Participants with at least one observation after baseline

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as The Course of Disease and Relapse Management During Treatment With Daivobet® Gel Under Consideration of Patient's Individual Application Habits Under Daily Use Conditions., measured over 1 year.

The primary outcome is described as the course of disease and relapse management during treatment with Daivobet® Gel, under participants’ individual application habits in daily-use conditions. Its stated unit is participants, and its description refers to the number of exacerbations and relapses during one year of observation. The outcome population is participants with at least one observation after baseline.

This outcome is intended to characterize how often disease worsening or relapse was recorded over follow-up. In general, counting events can describe recurrence over time in a way that a single assessment cannot. However, the registry describes the unit as participants and the parameter as a count of participants, while the outcome description refers to the number of exacerbations and relapses. The record does not clarify whether the reported measure would count participants experiencing an event, count events themselves, or present both. It also does not define exacerbation or relapse, or explain how repeated events in the same participant would be handled.

These details matter because a participant-based event indicator and a count of recurrent events answer different questions. The former concerns whether a participant experienced an event; the latter concerns the frequency of events, including possible recurrence. The registry record does not report a numerical primary-outcome result or an analysis explaining the operational definition. Thus the endpoint’s intended clinical subject is clear, but its exact measurement and observed value cannot be determined from the record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical interpretation begins with the distinction between a study aim and an analyzed result. The registry describes what the study intended to document, including a one-year assessment of exacerbations and relapses. It does not report an analyzed primary-outcome estimate. Without a value and an accompanying analysis, there is no effect estimate to interpret and no confidence interval from which to assess precision.

What does an observational design imply?

In general, an observational study records care and outcomes without assigning participants to treatment groups at random. It can describe what happened among people receiving care in the recorded setting. It is more difficult to make causal comparisons because participants’ treatment use and outcomes may be associated with other characteristics or decisions. For example, disease severity may influence care choices and also relate to later outcomes. This is a general design concern, not a claim about what happened to particular participants in this study.

The registry classifies this study as non-interventional and does not state an allocation method. No like-for-like control comparison is described. Thus, even if the record reported an outcome frequency, that frequency would describe the observed study population and would not by itself show what would have happened under a different treatment strategy.

What is the endpoint counting?

The endpoint metadata use participant-based wording, while the description refers to the number of exacerbations and relapses. In general, a binary outcome records whether each participant experienced an event; it does not retain the number of recurrences after the first event. An event-count outcome instead records how many events occurred and may include multiple events for one participant. The distinction affects both the meaning of the result and the statistical model used to analyze it.

The record does not explain which interpretation was used, define exacerbation or relapse, or state how repeated episodes were identified. The designation of the outcome as binary and the description of its unit therefore do not remove the ambiguity in the wording. The record also does not report the primary analysis or an outcome value, so no model choice or event frequency can be evaluated.

Why might recurrent-event data need special handling?

In general, recurrent events from the same participant are not necessarily independent. A participant’s event history can be related to later events, and participants may have different underlying event rates. A simple analysis that treats every event as unrelated can understate uncertainty when events cluster within participants. Over-dispersion is a general statistical issue that arises when observed count variability exceeds what a simpler count model expects; it can call for a model that allows greater variability. These are general considerations only. The registry record does not say that recurrent-event methods, count models, or over-dispersion adjustments were used.

Follow-up time also matters in general. Participants observed for different durations have different opportunities to experience events. An analysis may need to account for time at risk, censoring, or incomplete follow-up, depending on the outcome and design. The stated primary timeframe is one year, but actual follow-up completeness, censoring rules, and time-at-risk methods are not reported in the registry record.

How should uncertainty be assessed?

In general, a confidence interval expresses uncertainty around an estimated quantity and indicates which values remain reasonably compatible with the data under the analysis assumptions. It is not a guarantee that the true value lies within the interval, nor does it address biases that the study design or measurement process may introduce. The registry record reports no confidence interval for the primary outcome. It also does not provide a primary estimate or hypothesis test to interpret.

A p-value, when reported, concerns the compatibility of data with a specified statistical model and null hypothesis. It does not measure the size or clinical importance of an effect. No primary-outcome p-value or analysis is reported in this registry record. It would therefore be inappropriate to infer statistical significance or lack of significance from the absence of an analysis entry.

What can the analysis count tell readers?

The record lists zero analyses. This indicates that the registry record does not contain an analysis entry for the outcome; it does not establish why results are absent, whether analyses were conducted elsewhere, or whether the study collected the intended data. Those explanations are not reported in the registry record. Likewise, the record does not describe a prespecified statistical plan, handling of missing data, or any interim analysis. No conclusion about those procedures should be inferred.

In general, sample-size planning depends on assumptions about the outcome, the effect worth detecting, variability, allocation, and the intended analysis. A planning calculation is not an observed result and does not show that a study had a particular probability of detecting an effect after the fact. The registry record does not report a sample-size justification or planning assumptions for the study’s own design. The enrollment figure alone cannot establish statistical power or precision, particularly when the primary analysis population and outcome result are not reported.

Overall, sound interpretation would require a clear endpoint definition, an analysis population, a description of missing observations and follow-up, and an estimate with uncertainty. The registry record supplies the broad clinical aim and some design details, but not those analytic results. Statistical concepts can identify what information would matter; they cannot fill in the missing analysis.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists secondary outcomes concerning physician global assessment of psoriasis vulgaris severity and side effects. The severity assessment appears twice in the outcome list, while the record states four outcome measures. It does not explain the relationship between the listed entries and the outcome-measure count, identify which secondary outcome was prioritized, or report results for these measures.

Multiplicity arises in general when several outcomes or statistical tests are examined: the chance of at least one apparently notable finding can increase unless the analysis plan accounts for the number and relationship of tests. The registry record does not report a multiplicity strategy, a hierarchy among outcomes, or the number of statistical tests actually performed. It lists zero analyses, so there are no posted analysis results from which to assess how multiple outcomes were handled.

The primary-outcome population is defined as participants with at least one observation after baseline. The number meeting that definition is not reported in the registry record. There is no participant flow description, no account of missing outcome observations, and no explanation of how missing data were handled. The record also does not state whether analyses used all eligible participants, only those with observed follow-up, or another population definition beyond the primary-outcome wording.

In general, missingness can affect interpretation when participants without observed outcomes differ from those with observations. Complete-case descriptions may not represent the full enrolled group if missingness is related to disease course, treatment use, or other factors. This is a general concern, not evidence that any particular pattern occurred in this study. Without information on follow-up completeness and missing-data methods, the impact cannot be assessed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: psoriasis (0.2%), colon cancer (0.2%), sudden death (0.2%).

The registry records adverse-event figures for the All Eligible Patients group, with 561 at risk. The serious adverse-event count is 3, the other adverse-event count is 50, and the recorded death count is 2. The listed serious terms are Psoriasis, Colon Cancer, and Sudden death, each shown as 0.2%.

These entries are descriptive safety information. They do not, on their own, establish that an event was caused by Daivobet® Gel. The record does not report event timing, duration of treatment or follow-up for each participant, event definitions, adjudication procedures, or an assessment of causal relationship. It also does not explain whether a participant could contribute more than one event or how the adverse-event figures relate to the primary-outcome population.

The percentages attached to the serious terms should be read as the registry’s recorded values, not as comparative risks. There is no control group described, and no adjusted or comparative safety analysis is reported. The figures therefore cannot establish whether the recorded events occurred more or less often than they would have without treatment. The registry record also does not provide results for the secondary side-effects outcome beyond the adverse-event entries.

12. What the Result Does, and Does Not, Mean

The study’s stated aim was to document psoriasis disease course and relapse management during daily-use treatment with Daivobet® Gel, while considering participants’ individual application habits. The primary outcome was intended to address exacerbations and relapses over one year. The registry record includes the study’s enrollment and treatment description, but it does not report an analyzed primary-outcome result.

As a result, the posted record does not show how many participants experienced an exacerbation or relapse, how many events occurred, or how precisely either quantity was estimated. The ambiguity between a participant count and an event count further limits interpretation. Without a defined endpoint and numerical result, the study’s primary question cannot be answered from this record.

Even a reported frequency from this design would need to be interpreted as an observation among people receiving care in the study setting, rather than as proof that treatment caused the outcome. The study is non-interventional, no allocation method is stated, and no comparator group is described. Differences in disease course, application habits, follow-up, and clinical decisions could influence observed outcomes. The registry does not quantify or adjust for these factors.

The adverse-event entries also require restraint. They report counts and listed serious terms, but do not establish causality or permit a comparative safety assessment. The registry record does not provide results for the listed physician-assessed severity outcomes or a detailed account of missing observations.

Thus, the record establishes that a completed observational study was intended to describe long-term disease course and relapse management under daily-use conditions. It does not establish the size, direction, or precision of the primary outcome, and it does not support a causal claim about treatment benefit or harm. Those limits reflect what is reported in the registry record, not proof that no further data or analyses exist elsewhere.

13. Why This Trial Matters Statistically

This study raises statistical questions that are common in real-world clinical research. Treatment is described in daily-use conditions, and participants’ individual application habits are part of the stated purpose. Such a setting can capture how care unfolds outside a randomized comparison, but it also makes clear endpoint definitions, follow-up descriptions, and analysis methods especially important.

The primary outcome illustrates why measurement language matters. A participant count and a count of recurrent events represent different quantities. If participants can have repeated exacerbations or relapses, an analysis may need to account for recurrence and for the dependence of multiple events within one person. The registry record does not clarify which quantity was analyzed, so the endpoint cannot be interpreted with confidence as a particular type of count.

The study also highlights the distinction between observing outcomes and estimating treatment effects. A one-group observational description can be useful for documenting the course of disease and treatment use. Without a comparator and a stated allocation method, however, it cannot separate the treatment’s contribution from the natural course of disease or other influences on care. That distinction is important when readers encounter descriptive safety counts or outcome summaries.

Finally, a completed study record may still leave key statistical information unavailable. Here, the primary analysis, outcome estimate, uncertainty, missing-data handling, and analysis population size are not reported. The record therefore illustrates why transparent reporting requires more than an enrollment figure and an endpoint title. Definitions, denominators, follow-up completeness, and analysis results are needed to judge what the observed data can support.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this registry record constrain interpretation. Although the primary outcome is described as the number of exacerbations and relapses, its unit and parameter are participant-based. The record does not resolve whether the intended measure is participants with an event, recurrent events, or both. It also does not define exacerbation or relapse or describe how repeated episodes were distinguished.

The primary-outcome population includes participants with at least one observation after baseline, but the number in that population is not reported. No participant flow, baseline characteristics, follow-up completeness, or missing-data method is described. Therefore, it is not possible to determine how representative the analyzed population would be of the enrollment group, or whether incomplete observation could affect the recorded course.

The design is non-interventional, no allocation method is stated, and no comparator is described. The record does not report how treatment exposure, application habits, repeat courses, or medical surveillance were measured. It also does not provide enough information to assess confounding or variation in follow-up. These gaps preclude a causal treatment comparison.

The registry lists four outcome measures, including physician global assessment and side effects, but reports zero analyses. No primary estimate, confidence interval, statistical analysis plan, multiplicity approach, or sample-size justification is reported in the registry record. The adverse-event entries lack reported detail on timing, attribution, and participant-level exposure. These limitations mean that the record supports a description of study intent and selected safety counts, but not a quantitative conclusion about the primary outcome or comparative treatment effects.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation — NCT01707368.
• Registry record last updated 2018-09-24; status last verified 2018-01.
• Results first posted 2018-09-24.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01707368 is a completed, non-interventional study sponsored by LEO Pharma concerning psoriasis treatment with Daivobet® Gel in daily-use conditions. Enrollment was 561. The recorded regimen was once daily on plaque-affected areas, for up to 8 weeks on body skin areas except the scalp and up to 4 weeks on the scalp; treatment could be repeated under medical surveillance.

The primary outcome concerned exacerbations and relapses during one year, among participants with at least one observation after baseline. The registry record reports zero analyses and no numerical primary-outcome result. It does not describe a comparator, a statistical analysis plan, missing-data handling, or the size of the primary-outcome population. Adverse-event entries include 3 serious events, 50 other events, and 2 deaths among 561 at risk. These are descriptive counts and do not establish causation or comparative risk.